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OBJECTIVES In a retrospective study, we sought to evaluate the effect of left ventricular assist device
(LVAD) therapy on ventricular tachyarrhythmias in patients with advanced congestive heart
failure.
BACKGROUND Despite the increasing use of LVAD as a bridge to cardiac transplantation, our knowledge
regarding its effect on ventricular arrhythmias is currently limited to small series. Little is
known about the prevalence, predictors, and clinical consequences of ventricular arrhythmias
in LVAD recipients.
METHODS We reviewed the pre- and post-LVAD course of the last 100 consecutive adult patients to
receive a HeartMate LVAD (Thoratec Laboratories Corp., Pleasanton, California) at our
institution. All ventricular arrhythmias sustained for at least 30 s or requiring defibrillation
were analyzed. All documented pre- and post-LVAD sustained ventricular arrhythmias were
classified either as monomorphic ventricular tachycardia (MVT) or polymorphic ventricular
tachycardia (PVT)/ventricular fibrillation (VF).
RESULTS Our population had an average age of 51 years, had predominately ischemic cardiomyopathy
(63%), and a mean left ventricular ejection fraction of 20  10%. New-onset MVT was
observed in 18 patients who did not have MVT before LVAD placement. After LVAD,
new-onset MVT was 4.5 times more likely than elimination of previously present MVT
(p  0.001), whereas the effect of LVAD on incidence of PVT/VF was not significant. In a
multivariate Cox proportional hazards regression analysis, serum electrolyte abnormality was
an independent predictor of post-LVAD ventricular arrhythmias. Preoperative MVT did not
predict postoperative MVT.
CONCLUSIONS After LVAD placement, there is a significant rise in the incidence of de novo MVT. By
contrast, the incidence of PVT/VF was unaffected by LVAD placement. (J Am Coll

























fs the prevalence of advanced heart failure continues to
ncrease, the left ventricular assist device (LVAD) has
ecome an excellent bridge to cardiac transplantation and to
ossible other future alternative therapies (1,2). Our under-
tanding of post-LVAD ventricular arrhythmias is currently
imited to clinical data from a few small case series (3,4), and
ittle is known about the prevalence, predictors, and clinical
ignificance of post-LVAD ventricular arrhythmias. Even
ewer data are available with regard to the effects of LVAD
herapy on the prevalence and the electrophysiologic char-
cteristics of pre-existing ventricular arrhythmias. In this
etrospective study, we investigated the prevalence, predic-
ors, electrocardiography, and clinical outcomes of ventric-
lar arrhythmias in LVAD recipients.
ETHODS
ubjects. We reviewed the last 100 consecutive available
harts of patients to receive a HeartMate LVAD (Thoratec
aboratories Corp., Pleasanton, California) at the Colum-
ia University Medical Center between July 1997 and
arch 2001. All but two patients received a LVAD for
edically unresponsive advanced heart failure, whereas two
From the *Department of Medicine, †Division of Cardiology, and ‡Department of
ardiothoracic Surgery, Columbia University, New York, New York.o
Manuscript received June 22, 2004; revised manuscript received November 6, 2004,
ccepted January 25, 2005.atients received LVADs for uncontrollable ventricular
achyarrhythmias. All LVADs were implanted by the car-
iothoracic surgical staff at our institution and placed at a
eft ventricular (LV) apical site as previously described (5).
he majority of the patients received a LVAD as a bridge to
ardiac transplantation. Eighteen of the 100 patients had
iventricular assist devices placed at other institutions for
tabilization, until transfer to our institution for biventricu-
ar assist device explantation followed by HeartMate LVAD
mplantation. Another 12 patients required right ventricular
ssist device (RVAD) placement at our institution for severe
ight heart failure after LVAD implantation.
entricular arrhythmia analysis. All available past medi-
al records, physician and nurse notes, telemetry tracings,
etrieved implantable cardioverter-defibrillator (ICD) trac-
ngs, and 12-lead electrocardiograms (ECGs), both preop-
ratively and postoperatively, generated during the admis-
ion before LVAD implantation and during any subsequent
dmissions, were reviewed. All available preoperative and
ostoperative ventricular tachyarrhythmias lasting for at
east 30 seconds or requiring transthoracic defibrillation or
n ICD shock for termination were analyzed. Ventricular
rrhythmias were classified as monomorphic ventricular
achycardia (MVT), using the constancy of cycle length
rom one beat to the next, and the reproducibility of ECG
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eview by two electrophysiologists, each blinded to the
lassification of the other. Sustained ventricular arrhythmias
ot meeting the criteria for MVT were classified as poly-
orphic ventricular tachycardia (PVT), or ventricular fibril-
ation (VF). No distinction was made between sustained
VT and VF, (henceforth, PVT/VF) for analysis of the
esults.
Of the 100 consecutive patients initially selected into our
tudy, medical chart reviews identified 9 patients whose
roblem lists included ventricular tachyarrhythmia but for
hom no actual documentation of any ventricular arrhyth-
ia was available. These cases were not included in the
nalysis because without proper documentation, these ar-
hythmias could not be classified. Moreover, the distinction
etween MVT and PVT/VF was one of the main points of
ur analysis. The remaining 91 patients either did not have
history of any ventricular tachyarrhythmia, or had docu-
ented MVT, or PVT/VF, or both.
Available 12-lead ECGs were also analyzed in a blinded
ashion by two separate cardiac electrophysiologists, for
stimation of the approximate site of origin of MVTs, using
previously published algorithm (6). There was a 95%
greement rate between the two cardiac electrophysiolo-
ists. In cases of disagreement, a third, blinded electrophysi-
logist was asked to review the data for a final decision.
Several clinical and hemodynamic data, including blood
est results and postoperative LVAD flows, were also
nalyzed. For laboratory data, the last recorded values
ithin the 24 h before the ventricular tachyarrhythmia and
he first recorded values within 24 h after the ventricular
achyarrhythmia were used. Serum electrolyte abnormalities
nalyzed as correlates of ventricular tachyarrhythmias in-
luded hypokalemia, hyperkalemia, hypomagnesemia, and
ypocalcemia. These were defined as serum potassium
oncentration 3.5 mEq/l, 5.2 mEq/l, serum magnesium
oncentration 1.5 mEq/l, and corrected serum calcium
oncentration 8.0 mEq/l, respectively, in accordance with
he normal ranges of our hospital laboratory.
tatistical analysis. Proportions from different subgroups
ere compared by chi-square test. For comparisons within
mall groups in which the total data points were 40, a
isher exact test was used. In comparing the prevalence of
Abbreviations and Acronyms
ECG  electrocardiogram
ICD  implantable cardioverter-defibrillator
LV  left ventricular
LVAD  left ventricular assist device
LVEF  left ventricular ejection fraction
MVT  monomorphic ventricular tachycardia
PVT  polymorphic ventricular tachycardia
RVAD  right ventricular assist device
VF  ventricular fibrillationrrhythmias before and after LVAD therapy, McNemar’s
t
thi-square test was used. Continuous variables were com-
ared using a Student t test. To investigate the association
f postoperative ventricular arrhythmia and all-cause mor-
ality, a Cox proportional hazards survival analysis was used.
nce the transplant was complete, the patients were cen-
ored from survival analysis. A Cox proportional hazards
nalysis was also constructed to demonstrate the strength
nd independence of predictors of postoperative ventricular
rrhythmias. Based on the number of ventricular arrhythmia
vents observed after LVAD, we selected and tested five
linical factors for MVT and four for PVT/VF, as potential
redictors of post-LVAD ventricular arrhythmia. In this
nalysis, time to event was defined as time to onset of
entricular arrhythmia after LVAD implantation. The pa-
ients who underwent cardiac transplantation or died before
ventricular tachyarrhythmia event were censured from this
nalysis. A p value 0.05 was considered statistically
ignificant.
ESULTS
linical characteristics. Of the initial 100 patients whose
harts were reviewed, our population consisted of 91 pa-
ients who had either no pre-LVAD ventricular arrhythmias
r documented pre-LVAD ventricular arrhythmias. Their
linical characteristics are shown in Table 1. Only the two
atients whose indication for LVAD was uncontrollable
entricular arrhythmias were not receiving intravenous ino-
ropic therapy before LVAD.
rrhythmia prevalence. One hundred eighteen episodes
f documented sustained clinical ventricular arrhythmia
ccurred in 30 patients (3.9 episodes per patient) from 3
ears to 1 day before LVAD implantation. One hundred
eventy-nine episodes of sustained ventricular arrhythmia
ccurred in 32 patients (5.6 episodes per patient) from 1 day
o 126 days after LVAD placement. Of the 30 patients with
entricular arrhythmia before LVAD, 9 had documented
VT, 23 had documented PVT/VF, and 2 had both (Table
). Of the 32 patients with post-LVAD ventricular arrhyth-
able 1. The Clinical Characteristics of the Patient Population
Characteristics Total N  91 (%)
ge (yrs) 51  10
ale 74 (81)
schemic heart disease 57 (63)
VEF (%) 20  10
atients on amiodarone therapy before LVAD 38 (42)
atients with cardiac arrest prior to LVAD 28 (30)
atients with MVT or PVT/VF before LVAD 30 (33)
atients with MVT or PVT/VF after LVAD 32 (35)
atients with ICD implanted prior to LVAD 17 (19)
atients with NYHA functional class IV
before LVAD
81 (89)
atients on inotropic support prior to LVAD 89 (98)
atients on inotropic support after LVAD 91 (100)
CD  implantable cardioverter-defibrillator; LVAD  left ventricular assist device;
VEF  left ventricular ejection fraction; MVT  monomorphic ventricularachycardia; NYHANew York Heart Association; PVT polymorphic ventricular
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Assist Device and Ventricular Arrhythmias May 3, 2005:1428–34ia, 23 patients had documented MVT, 17 had docu-
ented PVT/VF, and 8 patients had both (Table 2). After
VAD, MVT was no longer observed during the follow-up
eriod in four patients with documented pre-LVAD MVT,
hereas the other five patients with pre-LVAD MVT
ontinued to have MVT after LVAD implantation. New-
nset MVT was documented after LVAD implantation in
8 patients who had no preoperative MVT (Table 2).
urthermore, 12 of these 18 patients had no pre-LVAD
entricular arrhythmia of any type. Thus, new-onset MVT
as 4.5 times more likely than elimination of previously
resent MVT (p  0.001) (Table 2). This finding remained
tatistically significant in the subgroup of patients with isch-
mic heart disease and in the group with LVEF between 15%
nd 40%. The presence of pre-LVAD amiodarone therapy
id not influence the significance of this finding; among the
atients with no prior amiodarone therapy, and among
hose with prior amiodarone treatment, there were equal
umbers of new-onset post-LVAD MVT.
After LVAD, PVT/VF was no longer observed in 16
atients who had this type of ventricular arrhythmia before
VAD placement, whereas PVT/VF occurred as a new-
nset ventricular arrhythmia in 10 patients who had not had
hese ventricular arrhythmias documented preoperatively
Table 2). The ratio of new-onset PVT/VF to the previ-
usly present PVT/VF, which disappeared after LVAD,
as not statistically significant (Table 2).
Repeating this analysis after excluding the two patients
ho received LVAD support for intractable ventricular
achyarrhythmias did not change our results. In this analy-
is, the number of patients with pre-LVAD MVT was 7;
owever, the number of patients with new-onset MVT after
VAD placement remained 18, and the number of patients
ith pre-LVAD MVT, who no longer had MVT after
VAD implantation also remained 4. Thus new-onset
VT remained 4.5 times more likely than the elimination
f previously present MVT.
The majority of the 32 patients who had post-LVAD
entricular arrhythmia had experienced the first episode of
entricular arrhythmia by the end of the first postoperative
eek (Fig. 1). All but 1 of the 32 patients had experienced
ost-LVAD ventricular arrhythmia by day 14 after LVAD
mplantation (Fig. 1), and after this period, no new-onset
entricular tachyarrhythmia in any of the remaining patients















MVT 9 23 4
PVT/VF 23 17 16
bbreviations as in Table 1.as observed until transplant or death.
(
slectrocardiographic site of origin of monomorphic
entricular tachycardia. An approximate left ventricular
LV) site of origin was defined for 11 post-LVAD MVTs,
or which, the 12-lead ECGs were available, using the ECG
lgorithm (6). Seven of these 11 MVTs (64%) were assigned
n LV apical site of origin (Fig. 2). Two of the remaining 11
atients had an inferior LV site of origin, 1 patient had an
nteroseptal site of origin, and 1 patient had a basal-septal
ite of origin. Five of the 11 available 12-lead ECG tracings
ad been recorded in patients who had new-onset MVT
fter LVAD implantation. Three (60%) of these five MVTs
ad an LV apical site of origin by the ECG algorithm used.
re-LVAD MVT had a mean cycle length of 355 82 ms;
n general, post-LVAD MVT was faster than preoperative
VT, manifesting a mean cycle length of 308  88 ms
p  0.04).
reatment of post-LVAD ventricular arrhythmias. One
undred twelve episodes (63%) of post-LVAD ventricular
rrhythmia were terminated immediately by an ICD shock
r transthoracic direct current cardioversion or defibrilla-
ion. Another 5% of the episodes were terminated by
ardioversion after 7.5  1.0 h of sustained ventricular
achyarrhythmia, and 14% of the MVTs were interrupted by
ntitachycardia ventricular pacing. Post-LVAD ventricular















5 18 18/4  4.5
p  0.001
7 10 10/16  0.63
p  0.17
igure 1. Of the 32 patients with post-left ventricular assist deviceLVA
ia
tLVAD) ventricular tachyarrhythmias, prevalence of arrhythmia onset is
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ighly frequent (5 episodes/day) in seven patients.
Ninety-three percent of ventricular tachyarrhythmia epi-
odes were treated with antiarrhythmic agents. Seventy-one
ercent of patients with ventricular tachyarrhythmias re-
uired two or more antiarrhythmic agents to prevent recur-
ence. The most common agent used was amiodarone
75%). Lidocaine was the second most commonly used
gent (41%). Procainamide, mexilitine, bretylium, and beta-
lockers were all used less commonly to control ventricular
achyarrhythmias.
Of the 32 patients with postoperative ventricular tachy-
rrhythmias, adequate suppression of arrhythmias could not
e achieved in 12 patients. Six of these patients died and the
ther six had cardiac transplantation. The mean number of
ays from the last documented ventricular tachyarrhythmia
o the end of follow-up was 4.9  1.2 in these 12 patients.
y contrast, of the remaining 20 patients in whom ventric-
lar tachyarrhythmias were suppressed, 3 patients died, and
7 patients underwent cardiac transplantation (p  0.049).
he mean number of days from the last documented
entricular tachyarrhythmia to the end of follow-up was
5.2  11.3 in these 20 patients. Furthermore, of these 20
atients, the ventricular arrhythmia came under control a
ean of 17.9  6.8 days after onset in patients with
ost-LVAD MVT, and 7.1  3.2 days after onset in
atients with PVT/VF. Amiodarone was more often the
rst drug to be started and the last to be used in the group
hat achieved ventricular arrhythmia suppression.
redictors of post-LVAD ventricular arrhythmias. We
enerated two separate multivariate models for predictors of
VT and PVT/VF. A Cox proportional hazards analysis
howed that pre-LVAD MVT was not a predictor of
ost-LVAD MVT (Table 3). Postoperative serum electro-
yte abnormality, as defined in the Methods section, was an
ndependent predictor of both post-LVAD MVT and
igure 2. An example of a 12-lead electrocardiogram tracing recorded dur
lectrocardiogram algorithm applied to the frontal and the horizontal axesVT/VF (Tables 3 and 4). Among the parameters analyzed CTable 3), the multivariate model identified only ischemic
eart disease as an additional independent predictor for
ost-LVAD MVT (Table 3). The same analysis applied to
ost- LVAD PVT/VF showed an inverse correlation be-
ween immediate postoperative LVAD flows and post-
VAD PVT/VF (Table 4).
linical consequences of post-LVAD ventricular
rrhythmias. Of the 32 patients with post-LVAD ventric-
lar arrhythmias, 6 (18%) required implantation of an
VAD for severe right heart failure, whereas 6 (10%) of the
9 patients without post-LVAD ventricular arrhythmias
equired implantation of an RVAD. This difference was not
ignificant. In the entire group with post-LVAD ventricular
rrhythmias, there was no significant change in laboratory
ndicators of inadequate systemic perfusion (blood urea
itrogen, creatinine) or right-sided heart failure (liver en-
ymes, prothrombin time) after termination of post-LVAD
entricular arrhythmias. The risk of embolic events was 23%
igher in patients with post-LVAD ventricular arrhythmias
5 of 32), compared with those who did not have post-
VAD ventricular arrhythmias (8 of 59). This increase was
ot statistically significant.
Over a follow-up period of one year after LVAD implan-
ation, 9 of the 32 (28%) patients with post-LVAD ven-
ricular arrhythmias died compared with 8 deaths in the
roup of 59 (14%) patients with no post-LVAD ventricular
rrhythmias (unadjusted hazard ratio  2.16, 95% confi-
st-left ventricular assist device monomorphic ventricular tachycardia. The
the QRS morphology suggests a left ventricular apical site of origin.
able 3. Clinical Parameters Analyzed as Potential Predictors of
ost-LVAD MVT
Hazard Ratio (CI) p Value
resence of MVT before LVAD 1.6 (0.48–5.4) 0.44
ostoperative electrolyte abnormality 5.2 (2.1–12.9) 0.0004
VAD flow immediately post-LVAD 1.1 (0.74–1.7) 0.54
schemic heart disease as etiology of
heart failure
4.6 (1.4–16) 0.015
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Assist Device and Ventricular Arrhythmias May 3, 2005:1428–34ence interval 0.83 to 5.62, p  0.11). Figure 3 shows the
urvival curves in these two groups. None of these deaths
ere sudden, because LVAD provided adequate cardiac
utput, at least temporarily, even when ventricular tachyar-
hythmias were intractable. The majority of the deaths were
aused by low output states, with or without sepsis or
leeding, whereas two patients died of fatal stroke.
ISCUSSION
his study presents the largest series to date, evaluating the
ffect of LVAD therapy on the presence and characteristics
f ventricular tachyarrhythmias. While ventricular tachyar-
hythmias were common in our population, present in
pproximately one-third of the patients, both preoperatively
nd postoperatively, LVAD therapy itself appeared to pro-
ote MVT in this group of patients. This conclusion is
upported by the significant increase in the new-onset MVT
fter LVAD therapy compared with the post-LVAD ab-
ence of previously present MVT in a small number of
atients. By contrast, LVAD therapy did not have a similar
ffect on PVT/VF. Furthermore, whereas the total number
f patients with ventricular tachyarrhythmias of any kind
efore and after LVAD was similar, post-LVAD ventricular
achyarrhythmia was more frequent, often incessant, and
esistant to multiple drug treatments. Our study did not
how a statistically significant relationship between post-
VAD ventricular tachyarrhythmias and all-cause mortality
r stroke. However, because this study was not powered to
how even a 50% relative risk increase in all-cause mortality,
ur data are inconclusive on these issues.
Two previously published series investigated the pre- and
ost-LVAD prevalence of ventricular tachyarrhythmias
3,4). Both studies were small and included fewer than 30
atients. The incidence of post-LVAD ventricular tachyar-
hythmias in these small series was 43% and 18%, respec-
ively, compared with 35% incidence we encountered in our
opulation. The conclusions of these two studies were
iscordant, one suggested a two-fold increase in ventricular
achyarrhythmia prevalence post-LVAD (3), whereas the
ther suggested a 36% reduction in ventricular tachyar-
hythmia prevalence (4). Our study has twice the power of
hese previous investigations, evaluated the changes in the
revalence of MVT and PVT/VF separately, and showed a
lear-cut increase in the incidence of MVT after LVAD. It
s important to emphasize that the increase in the incidence
f MVT we observed in LVAD recipients was not the result
able 4. Clinical Parameters Analyzed as Potential Predictors of
ost-LVAD PVT/VF
Hazard Ratio (CI) p Value
ostoperative electrolyte abnormality 3.2 (1.3–8.2) 0.015
VAD flow immediately post-LVAD 0.62 (0.43–0.89) 0.010
schemic heart disease 0.40 (0.072–2.2) 0.29
VEF (%) 1.0 (0.97–1.1) 0.72
bbreviations as in Tables 1 and 3.f transformation of PVT/VF into MVT by LVAD because
v
ghe majority of the de novo MVTs occurred in patients who
ad no pre-LVAD ventricular tachyarrhythmia of any kind.
Several previous case reports describe the use of LVAD to
reat frequent, drug-refractory ventricular tachyarrhythmias
7–10), similar to the two patients in our study, who
eceived a LVAD for uncontrollable MVT. These cases
how that ventricular tachyarrhythmias may or may not
ontinue after LVAD, but the clinical deterioration may be
alted with LVAD even in patients with continuing ven-
ricular tachyarrhythmias. Two small series have reported
he relative stability of LVAD patients despite recurrent
ustained ventricular tachyarrhythmias (3,11). One of these
eported a significant decrease in LVAD flow, by up to
.4 l/min, during sustained ventricular arrhythmias with
rompt return to baseline LVAD flow values after the
essation of ventricular arrhythmias without any evidence of
ignificant vital organ damage (3). Our observations corrobo-
ate this lack of end-organ damage with prolonged episodes
f ventricular arrhythmias in the presence of LVAD support.
rolonged periods of right ventricular PVT/VF or MVT
ay, in theory, predispose to marked right heart failure;
owever, our study did not show an increased incidence of
evere right heart failure in patients with post-LVAD ventric-
lar tachyarrhythmias.
There was a trend, which did not reach statistical signif-
cance, suggesting a possible association of post-LVAD
entricular tachyarrhythmias and all-cause mortality. How-
ver, our study was not powered to prove or disprove such an
ssociation, and further investigation in a larger group of
atients is needed to determine whether this association can
chieve statistical significance. This is especially important
ince the temporary hemodynamic stability, provided by the
VAD, may result in prolonged periods of untreated
ustained ventricular arrhythmias. Any association of pro-
onged episodes of ventricular arrhythmias with adverse
utcome, either increased incidence of stroke or increased
igure 3. Cumulative survival curves show all-cause mortality after left
entricular assist device (LVAD) implantation in the group with and the
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May 3, 2005:1428–34 Assist Device and Ventricular Arrhythmiasisk of mortality, would result in a more aggressive policy of
etection and treatment of post-LVAD ventricular arrhyth-
ias.
ossible mechanisms of post-LVAD ventricular arrhyth-
ias. Previous clinical observations have shown a strong
orrelation between myocardial scar and MVT (12). The
actors that promote PVT/VF may not necessarily be the
ame as those that promote MVT, although usually there is
n overlap between the etiologies of these morphologically
ifferent ventricular arrhythmias (13). Therefore, hemody-
amic benefit from the LVAD support might have played a
ajor role in the 20 patients in whom the ventricular
rrhythmias were finally suppressed. Improved hemody-
amic conditions may reverse myocardial ischemia and
ecrease ventricular wall tension, thereby exerting an anti-
rrhythmic effect. However, these factors may influence
VT and PVT/VF differently. For example, factors such as
yocardial ischemia, poor hemodynamic state, and ongoing
ntravenous pressor requirement, may play a more important
ole in triggering PVT/VF compared with MVT, which
ay be more dependent on the presence of old, but perhaps
lso newly acquired myocardial scar. This view is supported
y our observation that low LVAD flows, which may cause
yocardial ischemia and may also be associated with unsta-
le hemodynamic conditions, predicted PVT/VF but did
ot predict MVT. By contrast, the scar produced by the
pical insertion of the LVAD in-flow cannula may create a
ew substrate for MVT, thereby increasing the incidence of
VT even in the absence of myocardial ischemia or
nstable hemodynamic conditions. This possible explana-
ion is supported by the fact that the LV apex was the likely
ite of origin in three of the five de novo post-LVAD
VTs, for which 12-lead ECG documentation was avail-
ble. Furthermore, PVT/VF came under control in a shorter
eriod, 7.1 3.2 days after LVAD implantation, compared
ith MVT, which took longer, 17.9  6.8 days, to subside.
hese observations suggest, but do not prove, that factors
uch as hemodynamic improvement with LVAD support
nd discontinuation of intravenous pressors may have had a
reater impact on PVT/VF, compared with MVT, which
ay have required the antiarrhythmic effect of amiodarone
o a greater extent before coming under control. Finally,
VAD may have had an indirect effect on MVT by
ncreasing the efficacy of the antiarrhythmic agents resulting
rom the improvement in hemodynamic conditions.
It is not surprising that derangements in serum electrolyte
oncentrations correlated with the presence of any sustained
entricular arrhythmia after LVAD implantation, because
egardless of the nature of the arrhythmia substrate, these
erum electrolyte abnormalities may serve as initiating
riggers.
reatment of post-LVAD ventricular arrhythmias. Based
n our experience, the following methodical approach may
e reasonable for the treatment of post-LVAD ventricular
rrhythmias. Regardless of the type of ventricular tachyar-
hythmia, the first step should be the immediate assessment tf their hemodynamic consequences. Those that result in
ystemic clinical signs of hypoperfusion such as oliguria, a
ecrease in LVAD flows by 1.5 or more, or acute right heart
ailure should be terminated promptly by transthoracic
ardioversion or ICD shock if there is one in place. As a
econd step, serum electrolyte derangements should be
orrected promptly, again regardless of the type of ventric-
lar arrhythmia. Our results suggest that meticulous mon-
toring of serum electrolytes as early as possible is warranted
s a measure to possibly avoiding post-LVAD ventricular
rrhythmias. Our data also show that the majority of
atients who develop ventricular tachyarrhythmias after
VAD placement have them very early after the operation
Fig. 1), when there is prodigious intravenous pressor use.
specially for those patients with PVT/VF, weaning off
ressor support promptly, whenever possible, should be the
oal. Finally, in patients with MVT, amiodarone therapy
hould be started early, because it takes longer for this
entricular arrhythmia to come under control, which may
ot happen solely by improvement of hemodynamic condi-
ions, myocardial ischemia, and other reversible conditions.
tudy limitations. Our study was limited by its retrospec-
ive nature. This was especially a concern with regard to the
re-LVAD documentation of ventricular arrhythmias. De-
pite our efforts to carry out a very comprehensive clinical
eview of all available clinical material generated before
VAD implantation, it is possible that few patients had
entricular arrhythmias months or years before LVAD
lacement with no available documentation. Such lack of
ocumentation may result in underestimation of pre-
VAD MVT, or PVT, or both. Lack of documentation is
lesser problem for the duration of hospital stay, because
he patients are watched closely, and their cardiac rhythms
re monitored on telemetry. However, when the cardiac
hythm of an LVAD patient is no longer monitored
ontinuously, for example, after discharge from the hospital,
pisodes of self-terminating latent ventricular arrhythmias
ay go undetected because of the hemodynamic stability
rovided by the LVAD support. Such occurrences would
nderestimate the incidence of post-LVAD late ventricular
rrhythmias.
The average observation periods before and after LVAD
ere uneven by necessity, because the post-LVAD
ollow-up period is understandably limited by cardiac trans-
lantation in the majority of patients. Longer follow-up
eriods might allow observation of new MVT or PVT/VF,
hereby changing the incidence of post-LVAD ventricular
rrhythmias. This limitation, however, is unlikely to affect
he main observation of our study, the emergence of a
ignificant number of de novo MVT after LVAD implan-
ation, during a relatively short period, and mostly in
atients who had no pre-LVAD ventricular arrhythmia of
ny kind.
Other limitations involved the analysis and the interpre-
ation of the 12-lead ECG tracings. Even though the
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hus, bias could have been introduced in ECG interpreta-
ions. Finally, the difficulty in reviewing all the details
uring the complex intensive care given to the LVAD
ecipients limited our ability to report comprehensively on
he efficacy of the specific anti-arrhythmic agents used for
reatment of ventricular arrhythmias postoperatively. Thus,
ur study is not able to suggest a definitive pharmacologic
reatment strategy for post-LVAD ventricular arrhythmias.
onclusions. In the largest retrospective study to date
nvestigating the effect of LVAD therapy on ventricular
rrhythmias, we showed a significant increase in de novo
VT after LVAD therapy, with no similar increase in
ost-LVAD PVT/VF. The optimal modalities of anti-
rrhythmic therapy for ventricular arrhythmia suppression
n LVAD recipients need better definition. Whether post-
VAD ventricular arrhythmias are associated with an in-
reased risk of stroke or all-cause mortality remains unre-
olved and needs to be investigated further.
eprint requests and correspondence: Dr. Hasan Garan, Director
f Clinical Cardiac Electrophysiology, Professor of Medicine, Co-
umbia Presbyterian Medical Center, 161 Fort Washington Avenue,
uite 551, New York, New York 10032. E-mail: hg2017@
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